Thumbnail
Access Restriction
Open

Author El-Mas, Mahmoud M. ♦ Helmy, Maged W. ♦ Ali, Rabab M. ♦ El-Gowelli, Hanan M.
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword APPLIED LIFE SCIENCES ♦ BLOOD PRESSURE ♦ CYCLOSPORINE ♦ FIBROSIS ♦ GROWTH FACTORS ♦ HEART ♦ HYPERTENSION ♦ KIDNEYS ♦ RATS ♦ RECEPTORS ♦ SIGNALS
Abstract The immunosuppressant drug cyclosporine (CSA) is used with nonsteroidal antiinflammatory drugs (NSAIDs) in arthritic conditions. In this study, we investigated whether NSAIDs modify the deleterious hypertensive action of CSA and the role of endothelin (ET) receptors in this interaction. Pharmacologic, protein expression, and histopathologic studies were performed in rats to investigate the roles of endothelin receptors (ET{sub A}/ET{sub B}) in the hemodynamic interaction between CSA and two NSAIDs, indomethacin and celecoxib. Tail-cuff plethysmography measurements showed that CSA (20 mg kg{sup −1} day{sup −1}, 10 days) increased systolic blood pressure (SBP) and heart rate (HR). CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ET{sub A} (increases) and ET{sub B} (decreases) receptors. While these effects of CSA were preserved in rats treated concomitantly with indomethacin (5 mg kg{sup −1} day{sup −1}), celecoxib (10 mg kg{sup −1} day{sup −1}) abolished the pressor, tachycardic, and fibrotic effects of CSA and normalized the altered renal ET{sub A}/ET{sub B} receptor expressions. Selective blockade of ET{sub A} receptors by atrasentan (5 mg kg{sup −1} day{sup −1}) abolished the pressor response elicited by CSA or CSA plus indomethacin. Alternatively, BQ788 (ET{sub B} receptor blocker, 0.1 mg kg{sup −1} day{sup −1}) caused celecoxib-sensitive elevations in SBP and potentiated the pressor response evoked by CSA. Together, the improved renovascular fibrotic and endothelin receptor profile (ET{sub A} downregulation and ET{sub B} upregulation) mediate, at least partly, the protective effect of celecoxib against the hypertensive effect of CSA. Clinically, the use of celecoxib along with CSA in the management of arthritic conditions might provide hypertension-free regimen. - Highlights: • Chronic CSA causes hypertension and renal perivascular fibrosis in rats. • CSA increased and decreased renal ET{sub A} and ET{sub B} receptor expression, respectively. • CSA effects were abolished after co-treatment with celecoxib but not indomethacin. • ET{sub B} receptor blockade caused celecoxib-sensitive elevations in SBP. • Celecoxib protects against CSA hypertension via rectifying altered ET receptors.
ISSN 0041008X
Educational Use Research
Learning Resource Type Article
Publisher Date 2015-04-01
Publisher Place United States
Journal Toxicology and Applied Pharmacology
Volume Number 284
Issue Number 1


Open content in new tab

   Open content in new tab